Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Ces symbols : LLY save search
Erasca Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company to Evaluate ERAS-007 and Cetuximab Combination
Published: 2022-03-10 (Crawled : 23:00) - biospace.com/
ERAS | $1.79 0.0% 570K
|
|
| O: -1.75%
H: 6.29%
C: -0.43%
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.02%
H: 1.86%
C: 1.21%
eras-007 ces trial collaboration
Entos Pharmaceuticals Announces Senior Leadership Appointments to Expand Executive Team and Accelerate Growth
Published: 2022-03-03 (Crawled : 14:30) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 2.08%
H: 1.86%
C: 1.5%
LJPC | $6.22 0.0%
|
Health Technology
|
| O: 1.9%
H: 1.63%
C: -2.33%
als ces cel growth
Medicenna Announces Appointment of Clinical Advisory Board and Dr. Kapil Dhingra as Strategic Advisor
Published: 2022-03-03 (Crawled : 13:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 2.08%
H: 1.86%
C: 1.5%
MDNA | $0.157 -0.32% 1.3M
|
Health Technology
|
| O: 1.31%
H: 0.0%
C: -5.61%
ces
Merus Announces Financial Results for the Fourth Quarter and Full Year 2021 and Provides Business Update
Published: 2022-02-28 (Crawled : 22:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.26%
H: 0.0%
C: 0.0%
MRUS | $39.83 -1.58% -1.61% 800K
|
Health Technology
|
| O: 1.03%
H: 4.76%
C: 0.35%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.44%
H: 2.1%
C: 0.88%
financial results ces results
Cyclerion Announces CY6463 Clinical Pipeline and Corporate Updates
Published: 2022-02-24 (Crawled : 16:20) - ir.cyclerion.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 3.94%
H: 0.0%
C: 0.0%
CYCN | $3.315 12.62% 3.3K
|
Health Technology
|
| O: 0.4%
H: 3.0%
C: -3.87%
cy6463 ces
ProQR Announces Fourth Quarter and Full Year 2021 Operating and Financial Results
Published: 2022-02-24 (Crawled : 12:00) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -1.4%
H: 0.0%
C: 0.0%
PRQR | News | $1.965 5.65% 5.34% 130K
|
Health Technology
|
| O: -8.92%
H: 9.79%
C: 5.68%
financial results ces results
Lilly Announces the Institute for Genetic Medicine and $700 Million investment in Boston Seaport Site
Published: 2022-02-22 (Crawled : 12:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.46%
H: 0.69%
C: -0.03%
ARE A | $115.69 -0.7% 0.0% 940K
|
Finance
|
| O: 0.02%
H: 1.43%
C: 1.05%
genetic ces
Grey Wolf Therapeutics Announces Formation of Clinical Advisory Board in Anticipation of Advancing First-in-Class Immuno-Oncology Approach into the Clinic
Published: 2022-02-15 (Crawled : 13:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.84%
H: 3.44%
C: 3.04%
ces therapeutics
180 Degree Capital Corp. Portfolio Company, D-Wave Systems, Inc., Announces Intent to Become a Public Company Through a Merger With DPCM Capital, Inc. and Provides an Update on Legacy Private Portfolio Monetization Efforts
Published: 2022-02-08 (Crawled : 14:30) - globenewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.45%
H: 0.0%
C: 0.0%
TURN | $3.98 -0.25% 4.8K
|
Finance
|
| O: 0.97%
H: 8.67%
C: 5.98%
ces system one merge
Calidi Biotherapeutics Announces Appointment of Alfonso "Chito" Zulueta, Former President of International for Eli Lilly, to Its Board of Directors
Published: 2022-02-04 (Crawled : 00:20) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -2.52%
H: 0.0%
C: 0.0%
CTS S | $43.43 0.77% 0.0% 120K
|
Electronic Technology
|
| O: -1.38%
H: 0.0%
C: 0.0%
ces therapeutics iot
Lilly announces $1 billion investment in new manufacturing facility in North Carolina
Published: 2022-01-28 (Crawled : 19:00) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 0.33%
H: 3.25%
C: 3.2%
ces
Innovent Announces the Approval of Pemazyre® (pemigatinib) in Hong Kong Market for the Treatment of Adults With Locally Advanced Or Metastatic Cholangiocarcinoma
Published: 2022-01-24 (Crawled : 12:30) - biospace.com/
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -1.97%
H: 0.5%
C: -0.88%
pemazyre treatment ema ces approval
Innovent Announces the Approval of Pemazyre® (pemigatinib) in Hong Kong Market for the Treatment of Adults With Locally Advanced Or Metastatic Cholangiocarcinoma With A FGFR2 Fusion Or Rearrangement That Have Progressed After At Least One Prior Line Of Systemic Therapy
Published: 2022-01-24 (Crawled : 08:00) - prnewswire.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -1.97%
H: 0.5%
C: -0.88%
pemazyre treatment ema ces approval system therapy
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
GBR | $1.42 31.48% 11.27% 990K
|
Energy Minerals
KUKE | $2.88 2.49% 7.64% 360K
|
MPLN | $0.6502 -11.74% 4.51% 2.2M
|
Finance
CXM 4 | $11.34 -0.44% 4.27% 1.7M
|
Information
PVL 4 | $1.47 -0.68% 4.08% 77K
|
Energy Minerals
RNR 4 | $224.74 0.85% 3.52% 310K
|
Finance
PZG | $0.4431 0.48% 2.91% 150K
|
Non-Energy Minerals
DBRG | $17.3 0.06% 1.97% 1.2M
|
Finance and Insurance
OSK 4 | $117.72 0.05% 1.96% 370K
|
Producer Manufacturing
HYLN 4 | $1.29 -2.27% 1.55% 680K
|
Producer Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.